Literature DB >> 16343098

Elevated late-night salivary cortisol levels in elderly male type 2 diabetic veterans.

Hau Liu1, Dena M Bravata, Josel Cabaccan, Hershel Raff, Elisabeth Ryzen.   

Abstract

OBJECTIVE: Late-night salivary cortisol (LNSC) is reportedly highly accurate for the diagnosis of Cushing's syndrome (CS). However, diagnostic thresholds for abnormal results are based on healthy, young populations and limited data are available on its use in elderly populations with chronic medical conditions. The purpose of this study was to evaluate LNSC levels in elderly male veterans with and without diabetes.
DESIGN: Prospective evaluation of LNSC levels in male veterans. PATIENTS: One hundred and fifty-four participants with type 2 diabetes and 52 participants without diabetes. MEASUREMENTS: Participants underwent outpatient LNSC (2300 h) testing. Participants with elevated LNSC (> or = 4.3 nmol/l) underwent secondary testing, including 24-h urine free cortisol (24UFC, > 60 microg/day) and dexamethasone suppression testing (DST, serum cortisol > 50 nmol/l). Participants with positive secondary testing had a morning ACTH level analysed and either pituitary or adrenal imaging performed.
RESULTS: One hundred and forty-one diabetics and 46 controls (mean age 61 years) returned samples (91% overall). Average LNSC levels (nmol/l) in diabetics were significantly higher than in nondiabetics [median (interquartile range): 2.6 (1.8-4.1) vs. 1.6 (1.0-2.0)] and in those aged > or = 60 compared to < 60 [2.7 (2.0-4.3) vs. 1.9 (1.4-2.9)] (P < 0.001 for both). Thirty-one participants required secondary testing. Seventy-nine per cent of participants who underwent secondary testing had normal 24UFC and DST. No cases of CS have been diagnosed to date. Increasing age [odds ratio (OR) 2.0 per decade], current diabetes mellitus (OR 4.4), and elevated blood pressure (OR 1.3 per 10 mmHg increase in systolic blood pressure) were associated with abnormal LNSC results (P < 0.05 for each).
CONCLUSIONS: LNSC has been shown to be sensitive and specific in diagnosing CS in certain high-risk populations, primarily the young and middle-aged. The development of age- and comorbidity-adjusted thresholds may be warranted for LNSC testing in elderly subjects and in those with significant comorbidity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16343098     DOI: 10.1111/j.1365-2265.2005.02395.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  40 in total

1.  Reproducibility and performance of one or two samples of salivary cortisol in the diagnosis of Cushing's syndrome using an automated immunoassay system.

Authors:  C A Carrasco; M García; M Goycoolea; J Cerda; J Bertherat; O Padilla; D Meza; N Wohllk; T Quiroga
Journal:  Endocrine       Date:  2012-01-24       Impact factor: 3.633

Review 2.  Pros and cons of screening for occult Cushing syndrome.

Authors:  Antoine Tabarin; Paul Perez
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

3.  The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; John Newell-Price; Martin O Savage; Paul M Stewart; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2008-03-11       Impact factor: 5.958

Review 4.  Update on late-night salivary cortisol for the diagnosis of Cushing's syndrome: methodological considerations.

Authors:  Hershel Raff
Journal:  Endocrine       Date:  2013-07-10       Impact factor: 3.633

Review 5.  Cushing's syndrome: update on signs, symptoms and biochemical screening.

Authors:  Lynnette K Nieman
Journal:  Eur J Endocrinol       Date:  2015-07-08       Impact factor: 6.664

6.  Posttraumatic stress disorder and incidence of type-2 diabetes: a prospective twin study.

Authors:  Viola Vaccarino; Jack Goldberg; Kathryn M Magruder; Christopher W Forsberg; Matthew J Friedman; Brett T Litz; Patrick J Heagerty; Grant D Huang; Theresa C Gleason; Nicholas L Smith
Journal:  J Psychiatr Res       Date:  2014-06-09       Impact factor: 4.791

7.  Is the hypothalamic-pituitary-adrenal axis disrupted in type 2 diabetes mellitus?

Authors:  Hershel Raff; Steven B Magill
Journal:  Endocrine       Date:  2016-09-30       Impact factor: 3.633

Review 8.  Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?

Authors:  Sachin K Majumdar; Silvio E Inzucchi
Journal:  Endocrine       Date:  2013-01-25       Impact factor: 3.633

9.  Specificity of screening tests for Cushing's syndrome in an overweight and obese population.

Authors:  Smita K Baid; Domenica Rubino; Ninet Sinaii; Sheila Ramsey; Arthur Frank; Lynnette K Nieman
Journal:  J Clin Endocrinol Metab       Date:  2009-07-14       Impact factor: 5.958

10.  Morning cortisol levels and cognitive abilities in people with type 2 diabetes: the Edinburgh type 2 diabetes study.

Authors:  Rebecca M Reynolds; Mark W J Strachan; Javier Labad; Amanda J Lee; Brian M Frier; F Gerald Fowkes; Rory Mitchell; Jonathan R Seckl; Ian J Deary; Brian R Walker; Jackie F Price
Journal:  Diabetes Care       Date:  2010-01-22       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.